Abintus Bio
Dr. Ronald Levy M.D., is a scientist at Stanford University, where he specializes in lymphoma, including Non-Hodgkin’s Lymphoma, Burkitt’s Lymphoma and Hodgkin’s Disease. His research investigates how the immune system can be harnessed to fight lymphoma. His work has led to the concept that antibodies can be used as personalized anticancer drugs and to the development of an antibody-based drug, Rituxan, that is widely used to treat lymphoma. Dr. Levy’s work has been recognized with the American Cancer Society’s Medal of Honor, the Karnofsky Award from the American Society of Clinical Oncology, and others. He is a member of the National Academy of Sciences and of the Institute of Medicine.
This person is not in the org chart
This person is not in any offices
Abintus Bio
Abintus Bio is leading the field of in vivo immune cell reprogramming. Abintus Bio is pursuing products that modulate immune cells from within their native environment to enhance patient access and patient outcomes.